

Andrew C Scott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3875546/publications.pdf>

Version: 2024-02-01

11
papers

1,797
citations

1163117

8
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

3984
citing authors

#	ARTICLE	IF	CITATIONS
1	Ectopic activation of the miR-200c/EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. <i>Science Translational Medicine</i> , 2021, 13, eabg4328.	12.4	8
2	TOX is a critical regulator of tumour-specific T cell differentiation. <i>Nature</i> , 2019, 571, 270-274.	27.8	697
3	Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. <i>OncoImmunology</i> , 2019, 8, e1570778.	4.6	19
4	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	27.8	643
5	A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. <i>Journal of Clinical Investigation</i> , 2017, 127, 2705-2718.	8.2	63
6	Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. <i>Nature Biotechnology</i> , 2015, 33, 1079-1086.	17.5	134
7	A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias. <i>Blood</i> , 2015, 126, 2527-2527.	1.4	5
8	Wilms' Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches. <i>Blood</i> , 2015, 126, 98-98.	1.4	2
9	A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. <i>Blood</i> , 2014, 123, 3296-3304.	1.4	52
10	Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody. <i>Science Translational Medicine</i> , 2013, 5, 176ra33.	12.4	147
11	Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. <i>Blood</i> , 2012, 120, 2087-2097.	1.4	27